Group 1 - The company has approved a share repurchase plan with a budget between RMB 10 million and RMB 20 million, aiming to buy back its A-shares at a price not exceeding RMB 9.53 per share within 12 months [2][3] - As of July 31, 2025, the company has repurchased a total of 265,516 shares, representing 0.10% of its total share capital of 274,400,000 shares, with a total expenditure of RMB 1,967,393.92 [3][4] - The highest and lowest prices for the repurchased shares were RMB 7.86 and RMB 7.02 per share, respectively [3] Group 2 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [5]

证券日报网讯8月4日晚间，南新制药发布公告称，2025年7月份，公司未实施股份回购。截至2025年7月 31日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份265，516股，占公司总 股本的比例为0.10%。 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-030 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 265,516股 | | 累计已回购股数占总股本比例 | 0.10% | | 累计已回购金额 | 1,967,393.92元 | | 实际回购价格区间 | 7.02元/股~7.86元/股 | 一、回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第 二届董事会第十五次会议，审议通过了《关于以集中竞价交易方 ...

南新制药（SH 688189，收盘价：17.25元）8月4日晚间发布公告称，截至2025年7月31日，公司通过上 海证券交易所交易系统以集中竞价交易方式累计回购公司股份约26.55万股，占公司总股本约2.74亿股的 比例为0.1%，回购成交的最高价为7.86元/股，最低价为7.02元/股，支付的资金总额为人民币约197万 元。 （文章来源：每日经济新闻） 2024年1至12月份，南新制药的营业收入构成为：医药制造占比99.99%，其他业务占比0.01%。 ...

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

Group 1 - The company, Nanxin Pharmaceutical (688189.SH), announced a share buyback program, having repurchased a total of 265,516 shares as of July 31, 2025, which represents 0.10% of its total share capital [1] - The highest price paid for the repurchased shares was 7.86 CNY per share, while the lowest price was 7.02 CNY per share [1] - The total amount spent on the share buyback was 1,967,393.92 CNY, excluding transaction fees such as stamp duty and commission [1]

Market Overview - During the trading days from July 28 to August 1, all three major A-share indices experienced a pullback, with the Shanghai Composite Index down by 0.94%, the Shenzhen Component Index down by 1.58%, and the ChiNext Index down by 0.74% [1] - The Shanghai Composite Index closed at 3560 points with a trading volume of 684.6 billion yuan on Friday [3] Sector Performance - The pharmaceutical sector showed strong performance this week, with several stocks in the AI application, electronics, photovoltaic, and solid-state battery sectors also being active [1] - A total of 20 stocks saw a price increase of over 30%, with Nanjing New Pharmaceutical leading with a cumulative increase of 78.01% [4] Notable Stocks - Nanjing New Pharmaceutical's significant rise is attributed to its announcement regarding the potential acquisition of domestic pharmaceutical technology assets, although the deal is still in the planning stage and carries uncertainty [4] - Other notable gainers include Dongxin Co. (53.68%), Southern Road Machinery (53.38%), and Siquan New Materials (50.75%) [5] Trading Activity - A total of 71 stocks had a turnover rate exceeding 100%, with Beifang Changlong leading at 257.92% [6] - The sectors with high turnover rates included electronics, machinery equipment, and pharmaceuticals [6] Fund Flow - The banking and transportation sectors were favored by institutional investors, receiving net inflows of 2.224 billion yuan and 990 million yuan, respectively [8] - Conversely, sectors such as computers, non-ferrous metals, and electronics faced significant net sell-offs, each exceeding 10 billion yuan [8] Institutional Research - DeFu Technology attracted the most attention from institutions, with 238 firms participating in its research [14] - The focus of institutional research remains on sectors like electronic components, photovoltaic equipment, and industrial machinery [14] Financing Activity - New Yisheng topped the list for financing net purchases, amounting to 1.6 billion yuan, followed by Ningde Times and WuXi AppTec with 1.351 billion yuan and 1.123 billion yuan, respectively [12]

Market Overview - During the past week (July 28 to August 1), all three major A-share indices experienced declines, with the Shanghai Composite Index closing at 3559.95 points, down 0.94% for the week [2] - The Shenzhen Component Index closed at 10991.32 points, down 1.58%, while the ChiNext Index closed at 2322.63 points, down 0.74% [2] - Over 31% of stocks rose during the week, with 128 stocks increasing by over 15%, while 14 stocks fell by more than 15% [2] Top Gainers - Nanjing New Pharmaceutical (688189.SH) led the weekly gainers with a 78.01% increase, followed by Dongxin Technology (688110.SH) with a 53.68% rise [4] - Other notable gainers included Southern Road Machinery (603280.SH), Sixuan New Materials (301489.SZ), Dongjie Intelligent (300486.SZ), and Lide Man (300289.SZ), all with weekly gains exceeding 46% [4] Nanjing New Pharmaceutical - Nanjing New Pharmaceutical specializes in antiviral drugs and is currently planning to acquire a domestic pharmaceutical technology asset group, which has led to a significant stock price increase of nearly 70% over three days [5][7] - The company has faced continuous financial pressure, reporting net losses of -78.83 million yuan in 2022, -10.87 million yuan in 2023, and projected losses of -357 million yuan in 2024 [6] - The stock price surged by 17.01% and 20% on July 28 and 29, respectively, and reached a 20% limit up on July 31, closing at 17.14 yuan [7] Top Losers - Aimer Group (603511.SH) was the biggest loser, with a weekly decline of 23.19%, attributed to unmet performance targets leading to the repurchase and cancellation of restricted stock [9] - The company, which focuses on the design, production, and sales of lingerie and homewear, reported a revenue drop from 33.00 billion yuan in 2022 to 31.63 billion yuan in 2024, with a corresponding decline in net profit [10][12] - Aimer's stock experienced significant volatility, hitting a limit down on July 29 and closing at 15.97 yuan with a trading volume of 4.1 billion yuan [10]

Core Insights - The market has shown significant volatility, with some stocks experiencing dramatic increases while others have sharply declined, indicating a mixed sentiment among investors [1][3] Group 1: Stock Performance - Nanjing New Pharmaceutical has surged by 78%, driven by speculative interest in the innovative drug sector, despite lacking concrete agreements or performance backing [3] - A total of 50 stocks have dropped over 10%, with some like C Han Gao and Aimu shares plummeting by 20%, highlighting a trend of "three no stocks" (no performance, no liquidity, no major investors) [3] Group 2: Market Dynamics - The recent meeting by the Medical Insurance Bureau has positively influenced the innovative drug sector, with significant deals like the $2 billion GLP-1 drug sale by Shiyao Group boosting industry expectations [3] - The trading volume has decreased from 1.9 trillion to 1.6 trillion, indicating a shift in investor focus towards more stable and high-certainty stocks, while speculative and low-performance stocks are being abandoned [3] Group 3: Investment Strategies - Investors are advised to focus on stocks with strong policy backing, performance improvements, and state-owned enterprise support, as these are more likely to sustain growth [4] - Emphasis is placed on the importance of liquidity, with stocks lacking sufficient trading volume being considered traps, regardless of their low price [4] - The upcoming mid-year reports are expected to reveal both risks and opportunities, suggesting a need for careful analysis in the current market environment [4]

Market Overview - The Shanghai Composite Index fell by 0.94% this week, with six industries experiencing gains, led by the pharmaceutical and biotechnology sector, which rose by 2.95% [1] - The coal and non-ferrous metals industries saw the largest declines, with drops of 4.67% and 4.62% respectively [1] Fund Flow Analysis - A total of 211.86 billion yuan was net withdrawn from the two markets this week, with only the banking sector seeing a net inflow of 4.33 billion yuan [1] - The non-ferrous metals industry had the highest net outflow, totaling 25.99 billion yuan, followed by the computer industry with a net outflow of 20.45 billion yuan [1][2] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector had a net outflow of 4.68 billion yuan this week, despite a price increase of 2.95% [3] - Out of 474 stocks in this sector, 323 stocks rose, with notable gainers including Nanjing New Pharmaceutical (up 78.01%), Lide Man (up 46.45%), and Chenxin Pharmaceutical (up 40.88%) [3] - The sector also saw 36 stocks with net outflows exceeding 100 million yuan, with WuXi AppTec leading at 1.98 billion yuan [3][4] Top Gainers and Losers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: up 29.52% with a net inflow of 1.01 billion yuan - Anke Bio: up 25.93% with a net inflow of 0.36 billion yuan - Lianhuan Pharmaceutical: up 15.99% with a net inflow of 0.34 billion yuan [3] - The top losers included: - WuXi AppTec: down 4.64% with a net outflow of 1.98 billion yuan - Borui Pharmaceutical: down 0.14% with a net outflow of 0.71 billion yuan - Kanglong Chemical: up 0.33% with a net outflow of 0.51 billion yuan [4]